Introduction
Dendritic cells (DCs) are bone marrow-derived leukocytes that exert a sentinel-like function. 1 They are a system of potent antigen-presenting cells (APCs) specialized to initiate primary T cell immune responses. DCs are considered important elements in the induction of specific antitumor immune response and are viewed as potential vehicles for delivery of tumor-specific antigens, both in animals and in patients. As the most potent APCs in vitro and in vivo, DCs have been shown to play a key role in the induction of antigen-specific immune responses against bacteria, viruses, allergens and tumor antigens. They serve as essential constituents of the immune system triggering immune reactions and are therefore considered as promising tools for immunotherapy. DCs ultimately derive from hematopoietic progenitors, although little is known about their lineage of origin. They can be generated in vitro from CD34
+ cord blood or bone marrow progenitors in the presence of GM-CSF and TNF-␣, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] as well as from peripheral blood or cord blood monocytes in the presence of GM-CSF and IL-4 or IL-13. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] In vitro-differentiated DCs show functional and phenotypic characteristics of immature DCs, able to capture and process antigens, that can be further differentiated in vitro into mature DCs with microbial agents, inflammatory cytokines or CD40L. 1 For a long time, the critical role of DCs in cancer was underscored by numerous reports in which the presence of DCs in tumor tissues was associated with good clinical prognosis of the disease. [26] [27] [28] However, more recently, several groups have described multiple defective functions of DCs in animal models and in cancer patients. [29] [30] [31] [32] The major findings in these studies were the lack of expression of co-stimulatory molecules in tumor-associated DCs. For example, DCs infiltrating colon carcinoma were shown to express MHC class II molecules, but these cells did not express co-stimulatory molecules, 30 eg certain skin cancers where less than 1% of DCs expressed CD80 and CD86. 31, 33 Consistent with these findings, tumor-associated DCs have a low allostimulatory capacity, particularly if isolated from progressing metastatic lesions as in malignant melanoma. 34 A population of DC isolated from the peripheral blood of patients with breast, head or neck cancer demonstrated significantly reduced ability to stimulate allogeneic and Ag-specific T cell responses. 35, 36 DCs isolated from tumor-bearing mice were unable to induce effective peptide-specific and antitumor cytotoxic immune responses, and were therefore ineffective as a tumor vaccine. 37, 38 To investigate defective DC functionality in tumorbearing hosts, previous studies have shown that several tumorderived factors such as VEGF, IL-6, IL-10, M-CSF and gangliosides can affect DC maturation in vitro [39] [40] [41] as well as other yet unspecified factors, 42 and render tumor-specific T cells anergic through a variety of mechanisms, reducing the likelihood of effective CTL responses. All this accumulating evidence highlights the fact that DCs can be considered one of the key players of tumor escape from control by the immune system.
On the other hand, there is now some evidence that malignant cells of many tumor types may be immunologically recognized and eliminated. 43 The unique properties of DCs have suggested that they may have the potential to reverse the immunological unresponsiveness generally seen in cancer patients. 44, 45 This can occur through a more effective presentation of tumor epitopes that may be more efficient inducers of helper and cytotoxic T cells. At present, there is no doubt that, at least in animal models, regression of established tumors or protection against tumors can be effectively induced by DCs. [46] [47] [48] [49] A number of reports also show the clinical feasibility of DC-based immunotherapy in a wide variety of human cancers. [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] Many of these ongoing clinical trials, that will not be described here in detail, provided encouraging results, but the real clinical benefit of this promising approach is still yet to be validated.
At present, little is known about the relationship between DCs and hematologic malignancies, with this field rapidly growing. Initial reports show that DC numbers can be increased in certain hematological diseases such as Hodgkin disease, 66 but the significance of this observation is unknown. Acute myeloid leukemia (AML) is characterized by clonal proliferation of hematopoietic myeloid progenitor cells that do not differentiate into functional leukocytes. 67, 68 Self-renewal capacity of one or several leukemia-initiating cells is necessary to initiate the leukemic process, and is followed by a commitment of low proliferative blasts into particular lineages characterizing the different subtypes of AML. Interactions between DCs and AML cells might represent an attractive model where DCs can become a valuable therapeutic tool for the adjuvant treatment of leukemic patients. However, DC subsets in vivo may also be affected by leukemogenesis and may contribute to the escape of leukemia from immune control. The aim of this work is to shed further light on this paradoxical picture where the line between immune tolerance and immune defense is narrow.
Immunoregulatory dysfunction of leukemic DCs in vivo
The potency of DCs for induction of immune responses can be affected by a number of aspects related to their maturation stage and state of activation. As mentioned above, DCs in vivo might represent a favored target for cancer evasion from immune control through a number of different mechanisms, resulting in a lack of efficient immune response. The interference between DCs and hematological disorders, especially AML, is not yet well characterized. Numerous difficulties have to be overcome. One major issue being the lack of a simple and clear definition of a DC. In addition, uncertainty as to the ontogeny and differentiation pathways of DCs, limited and somewhat contradictory data as to the interrelationship, role and function of different DC subsets, raised unsolved questions. DCs are phenotypically and functionally heterogeneous in vivo. In humans, in addition to tissue-specific DCs, two distinct subsets of blood DCs have been characterized based on the differential expression of CD11c. 69 Myeloid DCs (MDC) and plasmacytoid DCs (PDC) were shown to be able to promote polarization of naive T cells into Th1 or Th2. [70] [71] [72] [73] The balance of these cells in vivo determines the character of cell-mediated immune and inflammatory responses. 74 Recently, for the first time, we investigated the status of circulating peripheral blood DCs in 37 AML patients belonging to different FAB subtypes. 75 First, we asked whether circulating DCs could be detected in the peripheral blood of patients with AML. Next, we examined the functional properties of these cells. We could show a dramatic quantitative imbalance in blood DC subsets among the majority of patients. Both MDC and PDC subsets were found to exhibit the original leukemic chromosomal abnormality as visualized by FISH. Leukemic PDC had impaired in vitro maturation capacity, a decreased allostimulatory activity and were altered in their ability to secrete IFN-␣ after microbial stimulation. Our results established a clear difference in the function of leukemic circulating DCs compared to their non-leukemic counterparts. Stimulation via CD40 pathway failed to enhance the allostimulatory capacity of PDC from leukemic patients, which is compatible with the absence or low expression of HLA-DR and costimulatory molecules. 75 Furthermore, defective function of leukemic PDC would have serious consequences on the induction of anti-leukemic immune response. The main distinguishing feature of PDC is their ability to secrete large quantities of IFN-␣. 76 The in vivo effects of type I IFN include a broad spectrum of cellular targets. [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] IFN-␣ could contribute in activating cytotoxic effector cells and helping to eradicate leukemic blasts. Thus, the PDC dysfunction can dysregulate the putative anti-leukemic immune response and can exert indirect potent immunosuppressive properties. Since AML encompasses a biologically heterogeneous group of clonal disorders of myeloid precursors, with multiple prognostic factors, therapeutic approaches and clinical outcomes, it is still difficult at this stage to draw conclusions as to the direct clinical relevance of expanded blood DCs in AML patients. Further studies are warranted to clarify these issues.
Furthermore, preliminary data from Chaperot et al 90 suggested that a rare sub-type of AML can arise from transformed cells of the lymphoid-related PDC subset. Although various aspects of this entity still remain controversial, 91 the analysis of malignant cells from seven patients showed that the majority of CD4 +
CD56
+ leukemic cells share some phenotypic and functional features with the normal PDC subset, suggesting that CD4 +
+ leukemic cells could represent the malignant counterpart of PDC. 90 These data need yet to be confirmed in larger series, and the exact origin of this specific AML sub-type is now under investigation by different collaborative groups. 91 The role of MDC in AML patients is less clear. Although immature circulating blood MDC have preserved maturation capacities after culture in vitro, 75 recent data suggest that immature monocyte-derived DCs can induce regulatory T cells both in vitro and in vivo. 92, 93 Thus, these expanded immature MDC might induce regulatory or suppressive T cells impairing the quality of anti-leukemia immune response. This critical issue is now under intensive investigation in our laboratory.
Our observation that leukemic PDC, like leukemic MDC, can exhibit the same original chromosomal abnormality of the myeloid leukemic clone, 75 adds some knowledge to the understanding of DC ontogeny. It has been proposed that human circulating blood DCs may belong to distinct lineages. 76, 94, 95 However, despite an ever growing body of data, the phylogenetic affiliation of these cells remains controversial since they can differentiate from both lymphoid 96 and myeloid 94 progenitors. Our finding of a clonal relationship between MDC and PDC is in line with other data demonstrating that plasmacytoid T cell lymphoma cells, related to the PDC subset, can share a common precursor with myelomonocytic leukemic cells obtained from the same patients. [97] [98] [99] Our results support evidence that leukemia initiating progenitors are located at the very early level of hematopoietic stem cells, but also raise the intriguing possibility of the in vivo existence of an early common DC progenitor (CDCP) capable of giving rise to MDC or PDC under specific circumstances that do not necessarily belong to distinct and completely independent lineages. This hypothesis is in line with recent data reporting in a mouse model the characterization of a DC-committed precursor population, which has the capacity to generate all the DC subpopulations present in mouse lymphoid organs, but which is devoid of myeloid or lymphoid differentiation potential. These data support an alternative model of DC development, in which there is an independent, common DC differentiation pathway. 100 Therefore, it can be proposed that an oncogenic event associated with the leukemic transformation, can affect this CDCP and thus, be responsible for the defective functions of leukemic DCs in vivo.
Overall, this rapidly growing body of data brings new insights towards understanding of AML biology, offers a unique opportunity to decipher the mechanisms regulating DC ontogeny, and provides evidence that DC subsets and dendritopoiesis in vivo are affected by leukemogenesis and may contribute to the escape of leukemia from immune control.
Potential therapy with leukemia-derived DCs
Allogeneic bone marrow transplantation has proven to be an efficient treatment for patients with AML. [101] [102] [103] [104] [105] [106] [107] This is mainly attributed to the so-called graft-versus-leukemia effect mediated by the donor-derived immune system, especially T cells. 108 Thus, modulation of the immune system appears to be an attractive modality for the treatment of AML patients, especially those patients at high risk of relapse who cannot benefit from allogeneic stem cell transplantation. More than 20 years ago, some patients with AML received pooled, irradiated allogeneic leukemic cells in order to enhance their immune system. 109 At present, donor lymphocyte infusions (DLI) following allogeneic stem cell transplantation is the treatment of choice for relapse in chronic and acute myeloid leukemia. 110 Unfortunately, DLI is less successful in the treatment of AML patients. One possible reason for this decreased efficiency could be related to the fact that AML blasts are poor APCs devoid of co-stimulatory molecules [111] [112] [113] [114] and thus, fail to induce a potent and sustained antileukemic immune response. 115 We and other investigators have described the successful differentiation of leukemia-derived DCs from patients with AML. The original observation that the leukemic blasts of AML may express the features of the well-known monocyte-derived DC subset was made by Santiago-Schwarz et al in 1994. 116 Subsequently and simultaneously with the MD Anderson group, we were able to show that myeloid blasts may be driven to differentiate ex vivo into fully functional DCs capable of inducing leukemia-specific CTL. 117, 118 These leukemia-derived DCs could be obtained after a short-term culture in the presence of GM-CSF, IL-4 and CD40L. They exhibited a typical DC morphology, had a phenotype of mature DCs, especially the expression of co-stimulatory molecules, and could induce a potent proliferative response in naive CD4
+ T cells, while still retaining the leukemic chromosomal abnormality of the original blasts as ascertained by FISH. These cells secreted significant amounts of IL-12p70, and in some cases highly efficient autologous leukemia-specific CTL were obtained. 117 All these features are in accordance with DC properties currently accepted for the characterization of DC subsets. 119 Similar findings have since been reported by other investigators. [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] The high number of efficient co-stimulatory, adhesion and MHC molecules present on the membrane of these leukemic DCs could allow recruitment and activation of the rare specific anti-tumoral T cells that are supposed to belong to the naive lymphocyte pool. Moreover, to overcome the absence of identified leukemia-associated antigens, in the case of leukemic DCs, tumor cells themselves are used as immunogens. The latter could allow the induction of a T cell response against a wide variety of peptides, which would avoid their escape from CTL specific for one peptide only. In addition, this approach can allow bypassing the potential obstacle represented by the defective function of DCs demonstrated in vivo.
Unfortunately, in all published studies, including the report from our group and despite the use of a great variety of cytokine combinations, leukemia-derived DCs could not be obtained from all AML patients. Furthermore, yields of leukemic DC were very heterogeneous between patients, even among patients with the same leukemia subtype. In all the aforementioned studies, it was not possible to postulate any characteristic of leukemic cells predictive for the ability to generate DC. Since leukemic blasts are heterogeneous at the stage of maturation, we raised the question of the nature of the blast compartment that can be induced to acquire DC features in vitro. Our aim was to identify a blast subset capable of giving rise to fully functional leukemic DCs after a shortterm culture with a minimal combination of cytokines. Such Leukemia a rapid and predefined culture protocol, avoiding patienttailored techniques, long-term in vitro manipulations and complex and expensive cytokine combinations would allow access to this strategy to the highest number of patients. We could demonstrate that in most cases, CD14
+ blasts are the cells capable of differentiating into fully functional DCs after a short-term culture (5 to 7 days) in the presence of GM-CSF and IL-4 or GM-CSF and clinical grade IL-13. For clinical application, these cells could also be grown in clinical grade serum-free medium (Mohty et al, unpublished observations) .
Another major feature of DC physiology concerns the expression of chemokine receptors. Chemokines and their receptors play a critical role in the selective attraction of various subsets of leukocytes and DCs. Along with the acquisition of adhesion and costimulatory molecules, the immune response requires a timely interaction among different cell types within distinct microenvironments. The migration of DCs to the secondary lymphoid organs is believed to be one of the critical events.
133 CCR-7 is a very important receptor for T lymphocyte and DC trafficking to secondary lymphoid organs through high endothelial venules. As a way of understanding the regulation of leukemia-derived DCs migration, we examined the chemokine receptor expression on their surface in comparison to normal mature monocyte-derived DCs. Flow cytometry analysis revealed that after maturation, leukemia-derived DCs do not express CCR-5, a marker of immature DCs, but could acquire the expression of CCR-7 (Mohty et al, unpublished observations). Although transmigration studies are needed before drawing firm conclusions as to the functional significance of CCR-7 expression, after injection in vivo, it could be hypothesized that these leukemia-derived DCs would be trapped in T cell areas of lymph nodes where the initiation of immune responses take place. In addition, for optimal efficiency, one could assume that leukemia-derived DCs must already retain at least some leukemia-related proteins avoiding the antigen capture step and homing directly into lymph nodes where they would be able to initiate an efficient anti-tumor immune response. In this respect, a critical parameter is to retain integrity of tumorassociated antigens during in vitro differentiation. All investigators who performed FISH analysis confirmed that leukemiaderived DCs still retain the same cytogenetic aberration expressed by the non-differentiated leukemic blasts. Therefore, leukemia-derived DCs from AML patients may retain at least some features of the malignant clone like some leukemia-related proteins associated with the cytogenetic abnormality. Although the latter does not necessarily mean that they will be efficiently presented to T cells, one could assume that leukemia-derived DCs, while directing a Th1 response profile, will help in generating antileukemic cytotoxic responses better than fresh tumor cells. Indeed, in our recent work, we have shown that CD14 + blast-derived DCs can drive naive T cells towards a Th1 response with secretion of IFN-␥ (Mohty et al, unpublished observations). It has been demonstrated that the immune balance (Th1/Th2 balance) controlled by cytokines produced by Th1 and Th2 cells plays an important role in immune regulation, including anti-tumor immunity. 134 The balance of these cells in vivo determines the character of cellmediated immune and inflammatory responses. 74 Although it remains unclear how Th1 or Th2 immunity is involved in in vivo anti-tumor responses, several studies suggested that Th1 dominant immunity is superior in the induction of cytolytic effectors. [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] The Th1 cells that produce IFN-␥ have been shown to exert a powerful anti-tumor effect, whereas a Th2 profile may have an opposite effect, that is, down-regulation of innate and acquired anti-tumor immunity. The corollary of these observations is that a Th1 profile may be cancer protective, whereas a Th2 profile may promote tumor growth and dissemination.
The strategy leading to induction or increase of AML cells immunogenicity while acquiring essential chemokine receptors for trafficking into secondary lymphoid organs, may help in vivo to generate anti-leukemia cytotoxic T cell effectors in an autologous setting, or identify AML tumor-associated antigens that might prove active as a cell-free vaccine. Moreover, this strategy is also ripe for therapeutic manipulations and refinement in the allogeneic setting. Prior to DLI, leukemiaderived DCs might be used in vitro to elicit a more active, specific and less toxic responder antileukemic T cells in the pool of allogeneic donor lymphocytes. This strategy can minimize the possible deleterious complications of graft-versushost disease usually associated with allogeneic DLI. 110 Studies of leukemic DCs provide new insights towards understanding both leukemogenesis and the physiology of DCs, and illustrate the fine line between immune tolerance and activation. In AML and other leukemias, the generation of potent tumor-specific cytotoxic effectors capable of tumor control may be subsequently counterbalanced by a variety of mechanisms leading to anergy. The availability of leukemiaderived DCs and their capacity to enhance tumor recognition is a promising approach to immunotherapy in AML, paving the way for therapeutic options in other hematological malignancies. The design of a clinical DC-based vaccine immunotherapy protocol requires a concise functional characterization of DCs as well as reflection on the crucial role of route and timing of vaccine delivery to ensure potent specific cytotoxic effectors and helper T lymphocytes. If DC-based therapy is to benefit patients, this will probably be in the setting of minimal residual disease following or accompanying other established therapies. The optimization of DC-based vaccines ranks on the same level as the development of sensitive techniques to monitor minimal residual disease and reliable methods of measuring patient responses to DC vaccines.
